Outcome measure | Intake M (SD) | 6 Month M (SD) | 9 Month M ( SD) | 12 Month M ( SD) |
---|---|---|---|---|
YSR Internalising | n = 430 | n = 346 |  | n = 382 |
  MDFT | 14.59 (9.75) | 10.96 (7.77) | N/A | 10.82 (8.87) |
  IP | 14.60 (9.56) | 11.99 (8.71) | N/A | 11.76 (9.23) |
YSR Externalising | n = 430 | n = 346 |  | n = 382 |
  MDFT | 21.57 (9.22) | 17.08 (8.61) | N/A | 15.38 (9.07) |
  IP | 19.73 (8.32) | 17.12 (9.21) | N/A | 15.86 (8.80) |
CBCL Internalising | n = 433 | n = 341 |  | n = 363 |
  MDFT | 20.14 (10.32) | 14.81 (9.75) | N/A | 13.08 (9.79) |
  IP | 21.12 (11.18) | 16.12 (10.90) | N/A | 13.96 (9.16) |
CBCL Externalising | n = 434 | n = 341 |  | n = 364 |
  MDFT | 26.25 (12.04) | 18.44 (10.68) | N/A | 16.34 (11.15) |
  IP | 23.84 (11.51) | 18.76 (12.39) | N/A | 15.35 (9.80) |
FES Conflict a | n = 429 | n = 345 | n = 308 | n = 357 |
  MDFT | 0.43 (0.21) | 0.59 (0.22) | 0.65 (0.15) | 0.59 (0.20) |
  IP | 0.45 (0.21) | 0.62 (0.20) | 0.67 (0.13) | 0.63 (0.21) |
FES Cohesion | n = 429 | n = 345 | n = 308 | n = 357 |
  MDFT | 0.63 (0.30) | 0.83 (0.27) | 0.80 (0.17) | 0.85 (0.25) |
  IP | 0.60 (0.29) | 0.79 (0.27) | 0.77 (0.18) | 0.81 (0.26) |